Nexentis Technologies Inc. Common Stock
NXTSStock
$5.47−90.16%52W
Market Cap$6.18M
P/E—
Div yield—
Beta1.74
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-76.86%
Price vs S&P 500 (4W)23.32%
VGM Score35.34
Market Capitalization$6.18M
Industry Peers — Pharmaceuticals(557)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NXTSNexentis Technologies Inc. Common Stock | — | D | D | $5.47 |
| LLYEli Lilly & Co. | D | B | B | $1143.94 |
| JNJJohnson & Johnson | D | C | C | $247.48 |
| ABBVABBVIE INC. | D | C | B | $242.72 |
| MRKMerck & Co., Inc. | C | C | B | $123.78 |
| NVSNovartis AG | C | C | C | $155.50 |
| AZNAstraZeneca PLC | C | B | C | $186.05 |
| NVONovo-Nordisk A/S | C | B | C | $47.98 |
| ABTAbbott Laboratories | C | C | D | $94.52 |
| PFEPfizer Inc. | B | C | D | $24.09 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $484.81 |
About
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.